<SEC-DOCUMENT>0001193125-15-288092.txt : 20150812
<SEC-HEADER>0001193125-15-288092.hdr.sgml : 20150812
<ACCEPTANCE-DATETIME>20150812160831
ACCESSION NUMBER:		0001193125-15-288092
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150807
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150812
DATE AS OF CHANGE:		20150812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		151047108

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d34794d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>August&nbsp;7, 2015 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 100</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: <U>(267)&nbsp;440-4200</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;1.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Entry into a Material Definitive Agreement</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;7, 2015, we entered into a
DNA Cancer Vaccine Collaboration Agreement (the &#147;Agreement&#148;) with MedImmune, Limited (&#147;MedImmune&#148;), the global biologics research and development arm of AstraZeneca. Under the Agreement, MedImmune will acquire exclusive rights to
our INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are
able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70 percent of cervical pre-cancers and cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging
evidence suggests that the benefits from immuno-oncology molecules, such as those in MedImmune&#146;s portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement, MedImmune will make an upfront payment to us of $27.5 million as well as potential future payments upon
reaching development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. We are eligible to receive up to double-digit tiered royalties on INO-3112 product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the broader collaboration, MedImmune and we will develop up to two additional DNA-based cancer vaccine products not included in our
current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. We will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales
for these additional cancer vaccine products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of the Agreement commenced on August&nbsp;7, 2015 and will expire on the date when
royalty or other payment obligations are no longer due, unless the Agreement is terminated in its entirety or on a country-by-country, research program-by-research program, or product-by-product basis sooner upon the occurrence of certain events as
described in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2015, we issued a press release, which file as Exhibit 99.1 to, and incorporate by
reference in, this Form 8-K current report </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated August 10, 2015</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;12, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d34794dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g34794img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>NEWS RELEASE </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS ENTERS INTO STRATEGIC CANCER VACCINE COLLABORATION AND LICENSE AGREEMENT WITH MEDIMMUNE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine
candidates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Inovio schedules conference call for 8:30am ET today; </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Go to inovio.com and click on &#147;webcast&#148; tab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; August&nbsp;10, 2015 &#150; Inovio Pharmaceuticals (NASDAQ: INO) today announced that it has entered into a license agreement and
collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement, MedImmune will acquire exclusive
rights to Inovio&#146;s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell
responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70 percent of cervical pre-cancers and cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging evidence suggests
that the benefits from immuno-oncology molecules, such as those in MedImmune&#146;s portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, MedImmune will make an upfront payment of $27.5 million to Inovio as well as potential future payments upon reaching
development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. Inovio is entitled to receive up to double-digit tiered royalties on INO-3112 product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within the broader collaboration, MedImmune and Inovio will develop up to two additional DNA-based cancer vaccine products not included in Inovio&#146;s
current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. Inovio will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net
sales for these additional cancer vaccine products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;David Berman, Senior Vice President and Head of the Oncology Innovative Medicines unit,
MedImmune, said: &#147;Today&#146;s collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-specific T-cell responses. The unique combination of our broad immuno-oncology portfolio with Inovio&#146;s
T-cell-activating INO-3112, which enhances cancer specific killer T-cells, has the potential to deliver real clinical benefits for patients.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, President and CEO, Inovio, said: &#147;Our licensing partnership with MedImmune
represents an important step in executing our immuno-oncology combination strategy and advancing Inovio&#146;s cancer vaccine R&amp;D pipeline with a leading cancer immunotherapy company. INO-3112 is progressing, with positive interim data generated
in an Inovio-initiated phase I study. We appreciate MedImmune&#146;s recognition of our ability to activate best-in-class killer T-cells in vivo and look forward to working with them on this collaboration.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today&#146;s agreement builds on the existing partnership between Inovio and MedImmune on two research and development collaborations in the infectious
disease area. Both efforts are funded by the Defense Advanced Research Projects Agency (DARPA) and support R&amp;D focused on Ebola, influenza, and bacterial infections. MedImmune has a strong heritage in infectious disease and vaccine innovation,
having developed the first monoclonal antibody approved by the US Food&nbsp;&amp; Drug Administration for the prevention of an infectious disease and the technology that led to the creation of an HPV vaccine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INO-3112 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s SynCon<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> DNA-based immunotherapies help the immune system activate disease-specific killer T cells to fight a targeted disease. HPV, the most pervasive sexually transmitted virus, causes numerous
pre-cancers and cancers. Inovio&#146;s HPV immunotherapy called INO-3112 targets disease associated with the high-risk HPV types 16 and 18, which are responsible for over 70% of cervical pre-cancers and cancers. INO-3112 combines Inovio&#146;s
VGX-3100, its immunotherapy targeting HPV-caused diseases, with its DNA-based immune activator encoded for IL-12. INO-3112 is in three clinical studies for cervical and head and neck cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earlier this year, Inovio reported preliminary data showing that INO-3112 generated significant antigen-specific CD8+ T cell responses in 3 of 4 patients with
head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. These positive results represent the first study and first report of antigen-specific T cell immune responses generated in cancer patients after treatment with a DNA
immunotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously in a phase II efficacy trial, treatment with VGX-3100 resulted in histopathological regression of late-stage cervical dysplasia
to early stage or no disease, meeting the study&#146;s primary endpoint. In addition, the trial demonstrated clearance of the HPV virus in conjunction with regression of cervical lesions, meeting the secondary endpoint. Robust T-cell activity was
observed in subjects who received VGX-3100 compared to those who received placebo. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MedImmune </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the
discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and
autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca&#146;s three global R&amp;D centers. For more information, please
visit www.medimmune.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AstraZeneca in Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncology is a therapeutic area in which AstraZeneca has a deep-rooted heritage. It will be potentially transformational for the company&#146;s future, becoming
the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and hematological cancers. These are being
targeted through four key platforms &#150; immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AstraZeneca </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription
medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions
of patients worldwide. For more information please visit: <U>www.astrazeneca.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and
treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and
collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more
information, visit www.inovio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, <U>jrichardson@inovio.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital
resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not
limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results
desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immune therapy and vaccine
products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive
future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential
opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend
them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth
in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, our Form 10-Q for the quarter ended June&nbsp;30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline
will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven
accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g34794img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g34794img001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MV!SP0:^BOB)\3?B7^T1\3YM"\-Z?J-UX?20G3] T^-BHC7@37&."W^TQVKG
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M\K=,*<!OMX$$9!R* %K\-_CE_P GA?$G_L8;K_T:U?N17X;_ !R_Y/"^)/\
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M=\8P"270LH'=MM?05(0".1FORM:'ZR?B)\"/B(OPS_:5T#Q#=3-!HTS&SUC
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MK"+?4].T*TM+N(.'"21PJC#()!P0>0<5UT^6LY%4;F*D 9ZUX/\ \-!>&O\
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M,'F&#_G7WGOH/RBER/6O O\ AH'PW_T(OQ(_\-MJO_QBD_X:"\-?]"/\1_\
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MN+$2!]JY$@M_,QCC?C)QD^AZA>66EZ)=ZCJ%S'96%K"TUS<S.%CAC4;F=F/
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0KYGEPHO[F/)=MS$L%D?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
